BR112018008076A2 - derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos - Google Patents

derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos

Info

Publication number
BR112018008076A2
BR112018008076A2 BR112018008076A BR112018008076A BR112018008076A2 BR 112018008076 A2 BR112018008076 A2 BR 112018008076A2 BR 112018008076 A BR112018008076 A BR 112018008076A BR 112018008076 A BR112018008076 A BR 112018008076A BR 112018008076 A2 BR112018008076 A2 BR 112018008076A2
Authority
BR
Brazil
Prior art keywords
methods
derivatives containing
redox centers
lapachone derivatives
redox
Prior art date
Application number
BR112018008076A
Other languages
English (en)
Other versions
BR112018008076B1 (pt
Inventor
Nunes Da Silva Júnior Eufrânio
Coelho Cavalcanti Bruno
Do O Pessoa Cláudia
Henrique Guimarães Da Cruz Eduardo
A. Boothman David
Silvers Molly
Luiz Braga Antônio
Original Assignee
Universidade Federal De Minas Gerais
The Board Of Regents Of The University Of Texas System
Universidade Federal Do Ceará
Universidade Federal De Santa Catarina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Minas Gerais, The Board Of Regents Of The University Of Texas System, Universidade Federal Do Ceará, Universidade Federal De Santa Catarina filed Critical Universidade Federal De Minas Gerais
Publication of BR112018008076A2 publication Critical patent/BR112018008076A2/pt
Publication of BR112018008076B1 publication Critical patent/BR112018008076B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

a presente invenção se refere a compostos contendo dois centros redox, incluindo um centro redox calcogênio. a invenção também se refere a uma composição farmacêutica de tais compostos e seu uso para preparar medicamentos para o tratamento de pacientes com câncer.
BR112018008076-4A 2015-10-20 2016-10-14 Derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos BR112018008076B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562244038P 2015-10-20 2015-10-20
PCT/US2016/056986 WO2017070012A1 (en) 2015-10-20 2016-10-14 Lapachone derivatives containing two redox centers and methods of use thereof

Publications (2)

Publication Number Publication Date
BR112018008076A2 true BR112018008076A2 (pt) 2018-10-23
BR112018008076B1 BR112018008076B1 (pt) 2024-03-12

Family

ID=58558234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008076-4A BR112018008076B1 (pt) 2015-10-20 2016-10-14 Derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos

Country Status (2)

Country Link
BR (1) BR112018008076B1 (pt)
WO (1) WO2017070012A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109020986A (zh) * 2018-08-28 2018-12-18 中南大学 喹啉醌并氧杂环衍生物及其制备方法和在抗肿瘤药物上的应用
CN109705095B (zh) * 2019-02-25 2021-06-08 山东大学 一种含三氮唑环的稠环对苯醌类cdc25蛋白磷酸酶抑制剂及其制备方法和应用
CN113368087A (zh) * 2020-03-10 2021-09-10 复旦大学附属华山医院 胡桃醌其衍生物及其在制备化疗脑肿瘤的药物中的用途
CN115215837A (zh) * 2022-06-29 2022-10-21 山东大学 一种含三氮唑环的稠环对苯醌类二聚体衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
WO2008066301A1 (en) * 2006-11-27 2008-06-05 Mazence Inc. Anticancer composition containing naphthoquinone-based compound for intestine delivery system
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases

Also Published As

Publication number Publication date
WO2017070012A1 (en) 2017-04-27
BR112018008076B1 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
BR112016030730A8 (pt) composto
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 311/92 , C07D 307/91

Ipc: C07D 311/92 (2006.01), C07D 307/91 (2006.01), A61P

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/10/2016, OBSERVADAS AS CONDICOES LEGAIS